Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
January 20, 2015  

Case-Coulter Translational Research Partnership (CCTRP)

This is the fourth year of the second phase of the Case-Coulter Translational Research Partnership (CCTRP) to support collaborative translational research projects that address unmet or poorly met clinical needs. The CCTRP seeks to reduce the market risk of promising new clinical products arising from the research programs of BME and other Case faculty. Successful projects will thus often focus on the development of prototype products, building relationships with companies, performing clinical feasibility studies, obtaining regulatory approval, and other activities that companies or business experts indicate are the essential last steps before a license can be negotiated or a startup launched. An overarching goal of the program is to foster research and development work likely leading to commercially relevant translational technologies within a three- to five-year horizon. Because the goals of all Coulter projects are to reduce market risk, all proposals are expected to reflect genuine business input, and all projects must include a “business advisor” as an important member of the decision making team.

Awards up to $200,000 will be considered if well justified.

Letter of Intent Deadline: February 13, 2015

For more information visit the BME website.

 
NIH Change to annual progress reports received on/after 10/1/14

National Institutes of Health (NIH) annual progress reports received on or after October 1, 2014 must include a section to describe how individual development plans (IDPs) are used to identify and promote the career goals of graduate students and postdoctoral researchers associated with the award.

See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-113.html.

 
Ohio Third Frontier (OTF), Ohio Development Services Agency

The goal of the Ohio Third Frontier Technology Validation and Start-Up Fund (TVSF) is to increase economic growth in Ohio through start-up companies that commercialize technologies developed by Ohio institutions of higher education and other Ohio not-for-profit research institutions. Two separate mechanisms have been set up to achieve these goals:

Phase 1 –Technology Validation The specific objectives of this phase are as follows:
• To generate the proof needed to move technology to the point that it is either ready to be licensed by an Ohio start-up company or otherwise deemed unfeasible for commercialization.
• To fund validation activities, such as prototyping, demonstrations, and assessment of critical failure points in subsequent development, scale-up, and commercialization.

Phase 2 – Start-Up Funds The specific objectives of this phase are as follows:
• To support Ohio start-up companies that have licensed technology developed at Ohio research institutions during the critical early life of the company, and accelerate the time to market of this technology.
• To generate the proof needed to either commercialize the technology or move the technology to the point where additional funds needed for commercialization can be raised.
• To fund activities in order to generate the needed proof.

The TVSF will support technology that falls within the following areas: Advanced Materials related to advanced polymers, ceramics, composites, carbon fibers and nanotubes and specialty metals and alloys; Aeropropulsion Power Management; Agribusiness and Food Processing; Fuel Cells and Energy Storage; Medical Technology related to imaging, surgical instruments/equipment, implant devices, and regenerative medicine; Software Applications for business and healthcare; Sensing and Automation Technologies; Situational Awareness and Surveillance Systems; Solar Photovoltaics; and Shale.

Potential CWRU Applicants - Contact:
Michael Haag, MS, MBA, Executive Director, Technology Management, 216-368-6106 or mhaag@case.edu.

For more information on the TVSF visit the Ohio Third Frontier website.

 
amfAR, The Foundation for AIDS Research

amfAR, The Foundation for AIDS Research, has announced the availability of funding to support research relevant to exploring HIV persistence and the potential for HIV eradication. amfAR has established a new funding mechanism known as Impact Grants to support the in-depth development of concepts where preliminary data have indicated genuine promise in curing HIV. Impact Grants are conducted over a four-year funding period with up to $2,000,000 in total funding (including up to 20% indirect costs) and should include basic, animal and clinical (in vivo or ex vivo) research. Impact Grants aim to directly inform clinical efforts to safely eliminate or control latent/persistent HIV reservoirs. Priority will be given to projects with a clear pathway to development of an implementable intervention in humans.

Total Cost Maximum: $2,000,000

Performance Period: 4 years (July 1, 2015 – June 30, 2019)

Portal Request Form Deadline: Friday, February 27, 2015, 3:00 PM ET
Letter of Intent Submission Deadline: Tuesday, March 3, 2015, 3:00 PM ET
Hardcopy of Signed Face Page By Mail: Tuesday, March 24, 2015

For more information and to review the complete RFP visit the amfAR website.

 

CDC: Economic Studies of Immunization Policies and Practices

Funding Opportunity Number: RFA-IP-15-001

The purpose of this Funding Opportunity Announcement is to obtain economic information about vaccines and immunization policies, programs, and practices using economic and decision analyses and other appropriate methods. The results of these economic studies will be used to help inform policy and the development of effective interventions. Three studies will be conducted, including an analysis of the financial, economic, and epidemiologic relationships between vaccine-preventable infectious diseases and chronic diseases in adult populations, and the opportunity costs for immunization of failure to prevent chronic diseases. Study 1 may include, but need not be limited to influenza and pneumococcal diseases and diabetes. Study 2 will focus on an estimation of the costs of norovirus disease. Study three will involve an analysis of issues related to provider reimbursement for adult vaccination services.

Application Deadline: March 3, 2015

For more information visit the CDC’s Full Funding Opportunity Announcement.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.